| 产品描述: | NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis. |
| 靶点: |
NLRX1 |
| 体外研究: |
Amelenodor (0、500 或 1000 mg/kg;口服管饲;7 天) 可降低 ALP 水平。 Amelenodor (1 和 10 mg/kg;口服管饲;0-24 小时) 可到达远端胃肠道。 |
| 参考文献: |
1. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.504 ml |
12.518 ml |
25.035 ml |
| 5 mM |
0.501 ml |
2.504 ml |
5.007 ml |
| 10 mM |
0.25 ml |
1.252 ml |
2.504 ml |
| 50 mM |
0.05 ml |
0.25 ml |
0.501 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |